clinical trial · NCT05836324
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Solid TumorsAdvanced Solid TumorsMetastatic Solid TumorsINCA33890bevacizumabFOLFIRIFOLFOXCetuximabADG126
brief summary
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
started
Jul 24, 2023
primary completion
May 3, 2029
completion
May 3, 2029
last updated
Jul 23, 2026
official title
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol